Zelluna ASA

After a year littered with clinical failures for its cancer vaccine UV1, Ultimovacs has managed to secure survival by combining with fellow Norwegian biotech Zelluna Immunotherapy. The deal is structu

Ultimovacs ASA bills its cancer vaccine UV1 as universal; this is clearly not, in fact, the case. The company admitted yesterday that the jab added nothing to standard of care in a Phase II trial in

“I’m optimistic when it comes to both the integration and the impact of transformative technologies across the life sciences industry,” said Jessica Federer , Bayer ’s former chief digital officer a

In a disappointment, Geron Corporation ’s first-in-class telomerase inhibitor imetelstat for anemia in patients with lower risk myelodysplastic syndromes (MDS) will be subject to a US Food and Drug A